LUNG Pulmonx Corp stock chart & analysis
Conviction 0HealthcareScan · Wed, Nov 4, 2026Pulmonx Corp (LUNG) closed at $2.82 (+3.68%) on Nov 4, 2026. Its latest daily candle is a shooting star. Price is above its 50-day and above its 200-day moving average. RSI(14) 66, RS Rating 96, -13.2% from its 52-week high, +27.6% year to date. Sector: Healthcare · Surgical & Medical Instruments & Apparatus.
Why LUNG moved
From the StockSetups movers recaps that covered LUNG, newest first. A recap states what was known that day.
- Close+29.4%
No company-specific news headline was on file for August 3. However, Pulmonx filed an earnings-related 8-K on July 29, as well as a Schedule 13G/A disclosing a stake change.
Top Stock Movers Today — August 3, 2026: Why HYFM, FUSE, LUNG, SDST & ATKR Surged →
Financials as of Wed, Sep 30, 2026 · quarterly.
LUNG technical analysis
Trend
LUNG is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 35.9% above the 50-day ($2.07) and 68.9% above the 200-day ($1.67). ADX(14) at 36 points to a strong, established trend. It meets 7 of 8 trend-template criteria.
Momentum
RSI(14) is 66, in the bullish half of its range. The MACD histogram is positive. Its RS Rating of 96 puts its weighted 12-month performance ahead of about 96% of the US market.
Volume and volatility
Volume on the latest session ran 1.4× its 20-day average. It trades about $3.1M a day on average. ATR(14) is $0.2476, 8.8% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.08) shows accumulation.
Key levels
The 52-week range is $1.13 to $3.25; price is 13.2% below the high and 149.6% above the low. The VWAP anchored at the 52-week high is $2.92, above price.
Performance
LUNG returned +11.9% (1 week), +58.4% (1 month), +37.6% (3 months), +118.6% (6 months), +54.1% (1 year), +27.6% (year to date).
About Pulmonx Corp
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
Surgical & Medical Instruments & Apparatus · Listed 2020 · 296 employees
Insider activity
SEC Form 4 transactions in LUNG · open-market 3 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Mead Dana G Jr. Director · Common Stock · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-09 |
Sullivan Tiffany Director · Common Stock · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-09 |
Melenikiotou Georgia Director · Common Stock · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-09 |
Burns Thomas William Director · Common Stock · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-09 |
Mead Dana G Jr. Director · Common Stock · 2026-06-05 | Other | — | — | 2026-06-05 | 2026-06-09 |
Ferrari Richard Director · Common Stock · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-09 |
Florin Daniel P Director · Common Stock · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-09 |
French Glendon E. III President and CEO · Common Stock · 2026-06-02 | Sell | 13.51K | $21K | 2026-06-02 | 2026-06-03 |
Rose Geoffrey Beran CHIEF COMMERCIAL OFFICER · Common Stock · 2026-06-01 | Sell | 1.78K | $3K | 2026-06-01 | 2026-06-03 |
French Glendon E. III President and CEO · Common Stock · 2026-06-01 | Sell | 4.17K | $6K | 2026-06-01 | 2026-06-03 |
SEC filings
EDGAR filings in LUNG · 7 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.